866-997-4948(US-Canada Toll Free)

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals

Published By :

GlobalData

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : N/A

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2016 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, September 2016 14
2.2.1 Shire Raises USD12.1 Billion in Public Offering of Notes 14
2.2.2 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 15
2.2.3 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 15
2.2.4 Sanofi Prices Public Offering of Notes for USD3.3 Billion 16
2.2.5 Allergan to Acquire Tobira Therapeutics in Tender Offer 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2016 19
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2016 20
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21
3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2016 21
3.1.1 Top M&A Deals in September 2016 22
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2016 - September 2016 23
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2016 25
3.2.1 Top Equity Offering Deals in September 2016 26
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2016 - September 2016 27
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2016 28
3.3.1 Top PE/VC Deals in September 2016 29
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2016 30
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2016 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2016-September 2016 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2016-September 2016 34
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2016 35
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2016 - September 2016 37
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2016 39
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2016 40
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 41
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2016 - September 2016 43
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2016 - September 2016 44
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 46
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2016 48
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2016 48
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2016 50
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2016 - September 2016 52
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2016 - September 2016 54
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2016 - September 2016 56
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2016 - September 2016 58
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2016 59
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2016 60
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2016 60
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 61
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2016 61
5.1.1 Oncology - Deals of the Month 62
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2016 65
5.2.1 Central Nervous System - Deals of the Month 66
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2016 68
5.3.1 Infectious Diseases - Deals of the Month 69
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2016 71
5.4.1 Cardiovascular - Deals of the Month 72
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2016 74
5.5.1 Immunology - Deals of the Month 75
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, September 2016 77
5.6.1 Gastrointestinal - Deal of the Month 78
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2016 80
5.7.1 Metabolic Disorders - Deal of the Month 81
6 Deal Summary by Geography 83
6.1 Pharmaceuticals & Healthcare, North America Deals, September 2016 83
6.1.1 North America - Deals of the Month 85
6.2 Pharmaceuticals & Healthcare, Europe, Deals, September 2016 87
6.2.1 Europe - Deals of the Month 88
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2016 90
6.3.1 Asia-Pacific - Deals of the Month 91
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2016 93
6.4.1 Rest of the World - Deals of the Month 94
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2016 - September 2016 95
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2016 - September 2016 97
8 Further Information 98
8.1 Methodology 98
8.2 About GlobalData 99
8.3 Disclosure information 99
8.4 Disclaimer 100

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, September 2016 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2016 20
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 22
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2016 22
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016 24
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 26
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2016 26
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 27
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 29
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2016 29
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2016 - September 2016 31
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2016 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2016 - September 2016 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 39
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2016 40
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 42
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016 45
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2016 - September 2016 47
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 49
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 51
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 53
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2016 55
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016 57
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016 59
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, September 2016 59
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2016 60
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2016 60
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 62
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 66
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 69
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 72
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 75
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 78
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 81
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 84
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 88
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 91
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 94
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 96
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 97

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), September 2016 19
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), September 2016 20
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 21
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016 23
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 25
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 27
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 28
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016 30
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), September 2016 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), September 2016 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 41
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016 43
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016 44
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 46
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 48
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 50
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 52
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016 54
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, April 2016 - September 2016 56
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), April 2016 - September 2016 57
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016 58
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 61
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 65
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 68
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 71
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 74
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 77
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 80
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 83
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 87
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 90
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 93
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 95
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2016 - September 2016 97

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *